Hypertension Research最新文献_第6页

Blood pressure elevations post-lenvatinib treatment in hepatocellular carcinoma: a potential marker for better prognosis

IF 4.3 2区医学

Hypertension Research Pub Date : 2025-02-18 DOI: 10.1038/s41440-025-02149-4

Keisuke Shibata, Yuichi Akasaki, Akihiro Tokushige, Mina Nitta, Shin Kawasoe, Takuro Kubozono, Kohei Oda, Kotaro Kumagai, Seiichi Mawatari, Mitsuru Ohishi

{"title":"Blood pressure elevations post-lenvatinib treatment in hepatocellular carcinoma: a potential marker for better prognosis","authors":"Keisuke Shibata, Yuichi Akasaki, Akihiro Tokushige, Mina Nitta, Shin Kawasoe, Takuro Kubozono, Kohei Oda, Kotaro Kumagai, Seiichi Mawatari, Mitsuru Ohishi","doi":"10.1038/s41440-025-02149-4","DOIUrl":"10.1038/s41440-025-02149-4","url":null,"abstract":"Lenvatinib is a tyrosine kinase inhibitor that effectively inhibits vascular endothelial growth factor signaling and is used for treating hepatocellular carcinoma. However, angiogenesis inhibitors often cause hypertension. Although lenvatinib-induced hypertension has been proposed as a potential surrogate marker for better prognosis, studies on blood pressure elevations and outcomes following lenvatinib initiation are limited. This study included 67 patients who underwent lenvatinib therapy at the Department of Gastroenterology, Kagoshima University Hospital, between May 2018 and December 2023. The median age of the cohort was 71 years, and 82.1% of the patients were male. The median blood pressure at admission was 128/73 mmHg, which significantly increased to 136/76 mmHg the day after lenvatinib administration. Grade 3 hypertension (≥160/100 mmHg) occurred in 37.3% of patients during hospitalization. The median increase in systolic blood pressure from admission to its peak during hospitalization was 26 mmHg. Patients who experienced an increase in blood pressure of ≥26 mmHg were classified into the blood pressure elevation group, which showed a significantly lower mortality rate than that of the blood pressure non-elevation group (35.3% vs. 81.8%, log-rank p = 0.007), even after adjusting for age, sex, disease stage, performance status, and liver reserve function. This study demonstrated that patients who experienced earlier blood pressure elevation after lenvatinib administration had lower overall mortality rates. These findings suggest that blood pressure elevations after lenvatinib initiation may serve as valuable prognostic indicators in patients with cancer undergoing lenvatinib therapy.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":"48 4","pages":"1542-1553"},"PeriodicalIF":4.3,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41440-025-02149-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of public health and economic impacts of dietary salt reduction initiatives on social security expenditures for cardiovascular disease control in Japan

IF 4.3 2区医学

Hypertension Research Pub Date : 2025-02-17 DOI: 10.1038/s41440-025-02108-z

Nayu Ikeda, Miwa Yamaguchi, Ikuko Kashino, Takehiro Sugiyama, Katsuyuki Miura, Nobuo Nishi

引用次数: 0

Correction: Impact of smoking status on incident hypertension in a Japanese occupational population

IF 4.3 2区医学

Hypertension Research Pub Date : 2025-02-17 DOI: 10.1038/s41440-025-02158-3

Ikumi Yamato, Yasuo Kansui, Kiyoshi Matsumura, Minako Inoue, Ai Ibaraki, Satoko Sakata, Hisatomi Arima, Kenichi Goto, Takanari Kitazono

引用次数: 0

Impact of patient care teams on blood pressure control in patients with hypertension: a systematic review and meta-analysis.

IF 4.3 2区医学

Hypertension Research Pub Date : 2025-02-17 DOI: 10.1038/s41440-025-02152-9

Yuichi Akasaki, Yasunori Suematsu, Kengo Azushima, Yuhei Shiga, Atsushi Sakima, Michihiro Satoh, Hisatomi Arima, Nobuhito Hirawa

{"title":"Impact of patient care teams on blood pressure control in patients with hypertension: a systematic review and meta-analysis.","authors":"Yuichi Akasaki, Yasunori Suematsu, Kengo Azushima, Yuhei Shiga, Atsushi Sakima, Michihiro Satoh, Hisatomi Arima, Nobuhito Hirawa","doi":"10.1038/s41440-025-02152-9","DOIUrl":"https://doi.org/10.1038/s41440-025-02152-9","url":null,"abstract":"Hypertension is a significant risk factor for cardiovascular diseases, with its global prevalence doubling over the past three decades. Despite advancements in antihypertensive therapies, approximately 50% of patients with hypertension fail to achieve their target blood pressure (BP) levels, underscoring the need for innovative care strategies. Patient care teams comprising multidisciplinary healthcare providers have shown promise in improving BP management. This systematic review and meta-analysis were aimed at evaluating the effectiveness of patient care teams involving physicians in hypertension management. To this end, PubMed, Cochrane CENTRAL, and IchuShi-Web were comprehensively searched and 61 randomized controlled trials including 64,857 participants were identified. Compared with usual care, interventions by patient care teams significantly reduced office systolic BP (mean difference: -6.31 mmHg; 95% confidence interval: -7.71 to -4.90) and decreased the risk of uncontrolled BP by 27% (risk ratio: 0.73; 95% confidence interval: 0.68-0.79). Subgroup analyses demonstrated consistent BP reductions across various team leadership roles, such as physicians, nurses, and pharmacists, and across different intervention durations. These findings highlight the effectiveness of team-based BP management in achieving improved BP control, regardless of team composition or the follow-up period. Multidisciplinary care offers a viable approach to addressing the unmet needs of patients with hypertension, potentially improving cardiovascular outcomes. This evidence supports integrating patient care teams into hypertension management, particularly in settings requiring physician oversight. Future research should focus on refining team structures and tailoring interventions to diverse healthcare environments to enhance their impact.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143440743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nighttime phenotype in patients with heart failure: beat-to-beat blood pressure variability predicts prognosis

IF 4.3 2区医学

Hypertension Research Pub Date : 2025-02-17 DOI: 10.1038/s41440-025-02156-5

Hiromitsu Sekizuka

引用次数: 0

The importance of hypertension awareness and adequate blood pressure control before intracerebral hemorrhage

IF 4.3 2区医学

Hypertension Research Pub Date : 2025-02-17 DOI: 10.1038/s41440-025-02161-8

Hajime Ikenouchi

引用次数: 0

Exploring the impact of cerebral small vessel disease on long-term prognosis in spontaneous intracerebral hemorrhage

IF 4.3 2区医学

Hypertension Research Pub Date : 2025-02-14 DOI: 10.1038/s41440-025-02150-x

Naruhiko Kamogawa

引用次数: 0

Correction: Effects of renal denervation on the kidney: albuminuria, proteinuria, and renal function

IF 4.3 2区医学

Hypertension Research Pub Date : 2025-02-14 DOI: 10.1038/s41440-025-02148-5

Daisuke Yamazaki, Yoshio Konishi, Kento Kitada

引用次数: 0

Efficacy of renin-angiotensin system inhibitors, calcium channel blockers, and diuretics in hypertensive patients with diabetes: subgroup analysis based on albuminuria in a systematic review and meta-analysis.

IF 4.3 2区医学

Hypertension Research Pub Date : 2025-02-14 DOI: 10.1038/s41440-025-02146-7

Daisuke Ichikawa, Wakako Kawarazaki, Sanae Saka, Tomohiko Kanaoka, Hirofumi Ohnishi, Hisatomi Arima, Shigeru Shibata

{"title":"Efficacy of renin-angiotensin system inhibitors, calcium channel blockers, and diuretics in hypertensive patients with diabetes: subgroup analysis based on albuminuria in a systematic review and meta-analysis.","authors":"Daisuke Ichikawa, Wakako Kawarazaki, Sanae Saka, Tomohiko Kanaoka, Hirofumi Ohnishi, Hisatomi Arima, Shigeru Shibata","doi":"10.1038/s41440-025-02146-7","DOIUrl":"https://doi.org/10.1038/s41440-025-02146-7","url":null,"abstract":"In hypertensive patients with diabetes, the effectiveness of renin-angiotensin system (RAS) inhibitors in improving mortality, cardiovascular events, and renal outcomes, compared to other antihypertensive drugs such as calcium channel blockers (CCBs) and diuretics, remains uncertain, particularly in the context of albuminuria. A comprehensive literature search was conducted using PubMed, the Cochrane Library, and the Japan Medical Abstracts Society databases up to October 2024. A meta-analysis of 12 randomized controlled trials, including 14,163 patients, was performed. RAS inhibitors showed no significant advantage over CCBs or diuretics for all-cause mortality (relative risk [RR]: 1.00, 95% confidence interval [CI]: 0.92-1.08, p = 0.98), myocardial infarction (RR: 0.64, 95% CI: 0.32-1.31, p = 0.22), stroke (RR: 1.14, 95% CI: 1.00-1.31, p = 0.05), composite cardiovascular events (RR: 0.93, 95% CI: 0.81-1.07, p = 0.45), or end-stage renal disease (RR: 0.88, 95% CI: 0.72-1.08, p = 0.21). Subgroup analyses stratified by albuminuria status revealed no significant benefits of RAS inhibitors, regardless of albuminuria presence. The findings emphasize the need for cautious interpretation due to limited sample sizes, wide confidence intervals, and low precision. These results highlight the importance of considering not only RAS inhibitors but also other antihypertensive drugs as the first-line choice for blood pressure control in diabetic patients, with careful attention to side effects and other relevant factors.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How potassium intake regulates sodium excretion in the kidney? Aldosterone-independent pathway in human

IF 4.3 2区医学

Hypertension Research Pub Date : 2025-02-14 DOI: 10.1038/s41440-025-02154-7

Hiromi Nakagawa, Emiko Kuribayashi-Okuma, Miho Inaba, Natsuki Sasadate, Takahiro Suzuki, Shigeru Shibata, Tatsuo Shimosawa

引用次数: 0